Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial
2005; Oxford University Press; Volume: 20; Issue: 10 Linguagem: Inglês
10.1093/ndt/gfh728
ISSN1460-2385
AutoresMario R Salcedo-Alejos, Felipe Banda-Espinoza, Martha Rodríguez‐Morán, Fernando Guerrero‐Romero,
Tópico(s)Blood Pressure and Hypertension Studies
ResumoBackground. Previous studies in type 2 diabetes have demonstrated the renoprotective effect of AT1-receptor antagonist drugs, but data on type 1 diabetic (T1DM) children are scarce. The aim of this study was to evaluate the effectiveness of the AT1-receptor antagonist irbesartan in reducing creatinine clearance rate (CCR) in non-hypertensive T1DM children with renal hyperfunction.
Referência(s)